Companies · Pharmaceuticals

Vpi Holdings Corp

NEW YORK · Pharmaceuticals

Diligence memoA one-page analyst read on Vpi Holdings Corp — recommendation, valuation, rhythm, risks.
$2.5M
Total raised · real
1
Rounds
Latest step-up
Top 70%
Sector rank · raised
Seed
Latest stage · inferred · Wed Dec 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Vpi Holdings Corp looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.18× the median modeled value of Seed Pharmaceuticals companies in 2007–2009 (25 peers) — value vs value, same stage and era.
  • Within the normal band (118% of peer median) for its niche.
Dormant
  • Last raise 16.5 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Vpi Holdings Corp behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
16.5 yr record
Peak capital year was 2009 with $2.5M across 1 filings.
Market position
ahead of 31% of Pharmaceuticals peers
Capital scale is ahead of 31% of Pharmaceuticals peers; modeled value is above 54% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2009: $2.5M across 1 filings.
  • Largest single filing was $2.5M on 2009-12-23.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Vpi Holdings Corp is one of 1613 Pharmaceuticals companies tracked from NEW YORK. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2009-12-23 Raised $2.5M (real) Modeled valuation $95M (est)$2.5M$95MSeed2009

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2009

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$95.1M
Base estimate est.
$1.9M
Conservative case
$746.2M
Upside case
$12.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
16.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
16.5 yr
On record since
2009
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.5M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.5× above median
This company$2.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.3× above median
This company$95.1M
Sector median$76.1M

Raised more than 31% of sector peers (real $). Modeled value above 54% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 25.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Sequoia Pharmaceuticals Inc · Seed Raised $3.8M · modeled $144.6M (est)Spring Pharmaceuticals, LLC · Seed Raised $6.1M · modeled $142.7M (est)Oceana Therapeutics, Inc. · Seed Raised $3.0M · modeled $114.1M (est)Supergen Inc · Seed Raised $3.0M · modeled $114.1M (est)Archer Pharmaceuticals, Inc. · Seed Raised $2.7M · modeled $102.7M (est)Cequent Pharmaceuticals Inc · Seed Raised $2.7M · modeled $100.9M (est)Anthill Technologies Inc · Seed Raised $2.6M · modeled $97.6M (est)Raptor Pharmaceuticals Corp. · Seed Raised $2.4M · modeled $90.8M (est)Groupe Athena, Inc. · Seed Raised $2.4M · modeled $89.6M (est)Mediquest Therapeutics Inc · Seed Raised $2.3M · modeled $87.8M (est)Bridge Pharmaceuticals, Inc. · Seed Raised $2.2M · modeled $83.3M (est)Vpi Holdings Corp (this company) Raised $2.5M · modeled $95.1M (est)Vpi Holdings Corp
CompanyStageRaised · realValue · estvs peer med.
Sequoia Pharmaceuticals IncSeed$3.8M$144.6M1.79×
Spring Pharmaceuticals, LLCSeed$6.1M$142.7M1.77×
Oceana Therapeutics, Inc.Seed$3.0M$114.1M1.42×
Supergen IncSeed$3.0M$114.1M1.42×
Archer Pharmaceuticals, Inc.Seed$2.7M$102.7M1.27×
Cequent Pharmaceuticals IncSeed$2.7M$100.9M1.25×
Anthill Technologies IncSeed$2.6M$97.6M1.21×
Vpi Holdings Corp this companySeed$2.5M$95.1M1.18×
Raptor Pharmaceuticals Corp.Seed$2.4M$90.8M1.13×
Groupe Athena, Inc.Seed$2.4M$89.6M1.11×
Mediquest Therapeutics IncSeed$2.3M$87.8M1.09×
Bridge Pharmaceuticals, Inc.Seed$2.2M$83.3M1.03×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2009-12-23$12.5M$95.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2009-12-23
    • First recorded raise — entered as Seed.
Intelligence
Modeled next raise
$4.0M
Modeled next size est.range $2.6M$6.4M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Geoffrey S. Raker5 other2009-12
Douglas M. Karp1 other2009-12
Joseph W. Leary2009-12
Kevin Connelly2009-12
Stephen M. McCune2009-12
Registry & provenance

Vpi Holdings Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1422522
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nautilus Neurosciences, Inc.PharmaceuticalsSeries B$53.3M$272.0Mnetwork2 shared operators · same sector
Acendrx, Inc.PharmaceuticalsSeed$2.5M$95.1Msame sector · same stage
Bioscience Pharma Partners, LLCPharmaceuticalsSeed$2.5M$95.1Msame sector · same stage
Spektron Systems, LLCPharmaceuticalsSeed$2.5M$95.1Msame sector · same stage
Cel Sci CorpPharmaceuticalsSeed$2.5M$57.4Msame sector · same stage
MPX Bioceutical CorpPharmaceuticalsSeed$2.5M$94.3Msame sector · same stage
Laurent Pharmaceuticals Inc.PharmaceuticalsSeed$2.5M$53.8Msame sector · same stage
Fiorello Pharmaceuticals, Inc.PharmaceuticalsSeed$2.5M$97.0Msame sector · same stage
Frequently asked
How much funding has Vpi Holdings Corp raised?
Vpi Holdings Corp has raised approximately $2.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Vpi Holdings Corp's estimated valuation?
Provath's modeled valuation for Vpi Holdings Corp is approximately $95.1M (modeled range $1.9M–$746.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Vpi Holdings Corp at?
Vpi Holdings Corp's latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Dec 23.
What does Vpi Holdings Corp do and where is it based?
Vpi Holdings Corp operates in the Pharmaceuticals sector, based in NEW YORK.
Explore related

See where Vpi Holdings Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Vpi Holdings Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.